Literature DB >> 10208168

Fragile X syndrome and selective mutism.

R J Hagerman1, J Hills, S Scharfenaker, H Lewis.   

Abstract

This is the first report that details an association between fragile X syndrome (FXS) and selective mutism (SM). This 12-year-old girl with heterozygous full mutation at FMR1 has a long history of social anxiety and shyness in addition to SM. Her sister also has the full mutation and a history of SM that resolved in adolescence. A beneficial response to fluoxetine and psychotherapy is described. The FMR1 mutation appears to be the first gene mutation associated with SM and further studies are recommended to assess what percentage of patients with SM have the FMR1 mutation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208168

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  14 in total

Review 1.  The use of medication in selective mutism: a systematic review.

Authors:  Katharina Manassis; Beate Oerbeck; Kristin Romvig Overgaard
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-11-09       Impact factor: 4.785

2.  Case 2: Developmental delay, especially language, in a toddler.

Authors:  Moshe Shapira; Zvi U Borochowitz
Journal:  Paediatr Child Health       Date:  2008-11       Impact factor: 2.253

Review 3.  Fragile X-associated disorders: a clinical overview.

Authors:  Anne Gallagher; Brian Hallahan
Journal:  J Neurol       Date:  2011-07-12       Impact factor: 4.849

Review 4.  Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Authors:  John A Tsiouris; W Ted Brown
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 5.  'More than 100 years of silence', elective mutism: a review of the literature.

Authors:  Louise Sharkey; Fiona McNicholas
Journal:  Eur Child Adolesc Psychiatry       Date:  2008-03-20       Impact factor: 4.785

6.  Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders.

Authors:  Allyn McConkie-Rosell; Liane Abrams; Brenda Finucane; Amy Cronister; Louise W Gane; Sarah M Coffey; Stephanie Sherman; Lawrence M Nelson; Elizabeth Berry-Kravis; David Hessl; Sufen Chiu; Natalie Street; Ajay Vatave; Randi J Hagerman
Journal:  J Genet Couns       Date:  2007-05-12       Impact factor: 2.537

Review 7.  Advances in the treatment of fragile X syndrome.

Authors:  Randi J Hagerman; Elizabeth Berry-Kravis; Walter E Kaufmann; Michele Y Ono; Nicole Tartaglia; Ave Lachiewicz; Rebecca Kronk; Carol Delahunty; David Hessl; Jeannie Visootsak; Jonathan Picker; Louise Gane; Michael Tranfaglia
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

Review 8.  Molecular medicine of fragile X syndrome: based on known molecular mechanisms.

Authors:  Shi-Yu Luo; Ling-Qian Wu; Ran-Hui Duan
Journal:  World J Pediatr       Date:  2015-11-07       Impact factor: 2.764

Review 9.  Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.

Authors:  Chi-Tso Chiu; Zhifei Wang; Joshua G Hunsberger; De-Maw Chuang
Journal:  Pharmacol Rev       Date:  2013-01-08       Impact factor: 25.468

10.  Clinic-based retrospective analysis of psychopharmacology for behavior in fragile x syndrome.

Authors:  Elizabeth Berry-Kravis; Allison Sumis; Crystal Hervey; Shaguna Mathur
Journal:  Int J Pediatr       Date:  2012-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.